Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1622 1624 1625 1629
This examiner grants 81% of resolved cases
Taylor V Oh is an examiner in Art Unit 1622 of Tech Center 1600, with 1774 resolved cases. He maintains an 81.2% allowance rate, suggesting a consistent grant record across a large dataset. The median time to allowance is 824 days, reflecting the processing speed for these 1774 cases.
For those seeking to enhance their prospects, an interview lift of 15.3% is observed. This increase over the 81.2% baseline indicates that personal interaction is a valuable component of his practice. Practitioners can use this 15.3% lift to navigate the 824-day pendency more effectively.
The examiner appears receptive to the boost in success that direct communication provides. The 824-day timeline is efficient, and the 81.2% allowance rate is a strong baseline for applicants. Utilizing the 15.3% lift can help resolve outstanding issues and secure a patent grant.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18818183 | PHARMACEUTICAL COMPOSITION COMPRISING 1-(3-CYANO-1-ISOPROPYL-INDOL-5-YL)PYRAZOLE-4-CARBOXYLIC ACID | Non-Final OA | LG CHEM, LTD. |
| 18262256 | USES OF MELANOCORTIN-4 RECEPTOR AGONIST | Final Rejection | LG CHEM, LTD. |
| 18860397 | PROCESS FOR THE PREPARATION OF [1,4,5]-OXADIAZEPINE DERIVATIVES | Non-Final OA | Syngenta Crop Protection AG |
| 18922313 | ANACARDIC ACID FOR INFLAMMATORY CONDITIONS | Non-Final OA | Vanderbilt University |
| 18832446 | THERAPEUTIC AGENT FOR CANCER | Non-Final OA | TOHOKU UNIVERSITY |
| 18792715 | Synthesis of MEK7 Inhibitors and methods of Use Thereof | Non-Final OA | Northwestern University |
| 18811575 | PHOSPHONIUM-BEARING CONJUGATED POLYELECTROLYTES | Non-Final OA | Board of Regents, The University of Texas System |
| 18269168 | COMPOSITIONS AND METHODS RELATED TO BICYCLO[2.2.1] HEPTANAMINE-CONTAINING COMPOUNDS | Final Rejection | The Brigham and Women's Hospital, Inc. |
| 18288338 | CERTAIN N-(1-CYANO-2-PHENYLETHYL)-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING CYSTIC FIBROSIS | Non-Final OA | Insmed Incorporated |
| 18863744 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | Non-Final OA | Janssen Pharmaceutica NV |
| 18850267 | ASCORBIC ACID DERIVATIVE OR SALT THEREOF, ADDITIVE FOR POLYMERIZATION INITIATION, POLYMERIZATION INITIATOR, CURABLE COMPOSITION PREPARATION KIT, CURABLE COMPOSITION, CURED PRODUCT, AND DENTAL MATERIAL | Non-Final OA | MITSUI CHEMICALS, INC. |
| 18729630 | PHARMACEUTICAL FOR TREATMENT OF NOVEL CORONAVIRUS INFECTION | Non-Final OA | Shionogi & Co., Ltd. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy